분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-07 14:06:16 , Hit : 1596
 J&J Wins U.S. Approval for Hepatitis C Combo With Gilead



Bloomberg News

By Anna Edney   November 06, 2014

--------------------------------------------------------------------------------

      Johnson & Johnson (JNJ:US) won U.S. approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc. (GILD:US)’s Sovaldi, making it the second all-oral treatment available for the most common form of the virus.

The Food and Drug Administration cleared the once-daily treatment for patients with hepatitis C genotype 1, J&J said yesterday in a statement. The combination allows Olysio to be used without the standard therapies including interferon, an injection that sometimes has flu-like side effects.

The price of hepatitis C treatments has been criticized by insurers and lawmakers since Foster City, California-based Gilead’s Sovaldi was approved in December with an $84,000 price tag for a full course of treatment. The FDA on Oct. 10 cleared Gilead’s Harvoni, a once-daily pill that treats patients who have the most common form of the virus without using the older drugs. Harvoni has an estimated cost of $94,500 for 12 weeks.

Video: Stockton, CA, Wins Court Approval of Bankruptcy Plan

J&J hasn’t changed the $66,000 price for 12 weeks of therapy with Olysio since it was first cleared for use with older medicines in the U.S. a year ago, said Rebecca Tillet, a company spokeswoman. J&J plans to work with insurance companies and other payers to ensure it continues to provide access to patients, she said in a telephone interview.

“There are a lot of different patients needs,” she said. “We think Olysio will play a meaningful role in that mix.”

Patient Population

About 3.2 million people in the U.S. have hepatitis C, which can cause liver cirrhosis according to the Centers for Disease Control and Prevention. The most common form of the virus is genotype 1, which affects about 75 percent of patients. J&J, based in New Brunswick, New Jersey, and Swedish drugmaker Medivir AB (MVIRB) sell Olysio. The drug, in combination with ribavirin and interferon, can treat patients in 24 weeks, half the time of older medicines.

Video: Apple Wins in Court, Won’t Pay $93.7M Fine

J&J, the world’s largest health-care products company, reported Olysio revenue (JNJ:US) of almost $2 billion in the first three quarters of this year. Sovaldi has generated $8.6 billion in sales during the same time period.

Patients have been able use J&J’s Olysio and Gilead’s Sovaldi together without FDA clearance at a cost of $150,000. Doctors may prescribe drugs approved for specific diseases to treat other ailments in a practice called off-label use.

The drugs are part of a push to shorten treatment times while improving cure rates and eliminating unpleasant side effects. Older drugs include Merck & Co.’s Victrelis and Vertex Pharmaceuticals Inc. (VRTX:US)’s Incivek.

Video: Nurse Wins Freedom From New Jersey Ebola Quarantine

The FDA approved the combination treatment for a standard 12 weeks of therapy if patients don’t have cirrhosis and 24 weeks for those who do, according to the drug’s prescribing label.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editors responsible for this story: Crayton Harrison at tharrison5@bloomberg.net Andrew Pollack, James Callan







807   간 이식 환자들의 C형 간염을 완치시킨 새로운 치료법  이성욱 2014/11/14 1736
806   간 이식 환자들의 C형 간염에 효과적인 병용 요법  이성욱 2014/11/13 1670
  J&J Wins U.S. Approval for Hepatitis C Combo With Gilead  이성욱 2014/11/07 1596
804   에볼라에 대한 반응과 유전적 요인  이성욱 2014/11/04 1346
803   실험실에서 만든 인공위장  이성욱 2014/11/04 1303
802   거울이미지 RNA효소와 생명이 기원  이성욱 2014/11/03 1558
801   어떻게 복잡한 생명은 진화했는가?  이성욱 2014/10/31 1669
800   인간 녹아웃을 연구하는 유전학자들  이성욱 2014/10/31 1656
799   As the RNA World Turns (Either Way, with Cross-Chiral Enzyme)  이성욱 2014/10/31 1411
798   암의 우군-엑소좀(exosome)  이성욱 2014/10/29 2866
797   이웃의 정상세포를 감염시키는 암세포  이성욱 2014/10/27 1546
796   피부암 외에도 다른 위험성이 있는 햇빛  이성욱 2014/10/24 1558
795   Novartis Extends Deal to Use SomaLogic Proteomics Technology  이성욱 2014/10/23 1363
794   여성은 남성보다 현명한 의사결정자일까?  이성욱 2014/10/23 1525
793   스위칭 오프할 수 있는 리보자임(ribozyme)의 개발과 유전자치료 (우리실험실 결과소개)  이성욱 2014/10/17 2404
792   간에 암 전이가 어떻게 발생하는가  이성욱 2014/10/17 1767
791   CAR T 세포를 이용한 효과적인 항암 치료법  이성욱 2014/10/15 2137
790   Harvoni, a Hepatitis C Drug From Gilead, Wins F.D.A. Approval  이성욱 2014/10/14 1920
789   20년간 숨어 있던 폐암의 비밀  이성욱 2014/10/14 1549
788   특정 염색체 구조가 중요 유전자 조절  이성욱 2014/10/14 1941

[이전 10개] [1]..[21][22][23] 24 [25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN